Results 201 to 210 of about 10,858,974 (235)
Talimogene Laherparepvec (T-VEC)
Talimogene laherparepvec (T-VEC, IMLYGIC®) is the first approved oncolytic virotherapy for the treatment of patients with advanced melanoma. As the drug is administered intratumorally, it is mainly suitable for the treatment of (sub)cutaneous lesions.
Zdzienicki, Marcin +3 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Biological Therapy, 2021
Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a ...
Ahmad Alamer +2 more
exaly +3 more sources
Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a ...
Ahmad Alamer +2 more
exaly +3 more sources
The Transformation Matrices of Vec a to Vec A^T for Diagonal Matrix [PDF]
This study aims to discusses the transformation matrices of vec A to vec A^T for diagonal matrix. The matrix used is a 4 x 4 diagonal matrix assuming that two pairs of elements are located on the main diagonal with the same value.
Yulianti, Lyra +2 more
exaly +2 more sources
T-VEC Oncolytic Viral Therapy Shows Promise in Melanoma
Nature Reviews Clinical Oncology, 2015David Killock
exaly +2 more sources
Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective
Journal of Immunotherapy, 2022Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a (American Joint Committee of Cancer; AJCC 7th edition) unresectable melanoma.
Viola, Franke +6 more
openaire +2 more sources
Talimogene laherparepvec (T-VEC) as cancer immunotherapy
Drugs of Today, 2015Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer ...
F J, Kohlhapp, A, Zloza, H L, Kaufman
openaire +2 more sources
Oncolytic Viruses: T-VEC and Others
2017Immunotherapy has become a standard for treatment of several advanced cancers such as melanoma, lung cancer, and head and neck cancer. Lymphocyte-rich tumor microenvironment is a predictor factor for response to immunotherapy. Although, theoretically, these tumor-infiltrating lymphocytes should be highly immunogenic, it has been shown that the tumor ...
Rutika Mehta, Igor Puzanov
openaire +1 more source

